EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Expert Q&A

1. What exactly is the clinic buying—and which expenditure can it control?

Dose Diligence research deskSection 06 · Page 4 of 22Last updated 17 Nov 2026

Framing: classify the transaction before discussing savings. LillyDirect describes a patient-access experience using licensed third-party dispensing pharmacies. NovoCare describes electronic prescribing followed by patient account setup, payment and home delivery. Those descriptions do not establish clinic wholesale purchasing rights. (lilly.com)

Put to: Adam Fein and Jesse Dresser.
Buyer owner: CFO, supported by procurement and counsel.

Why it matters: The buyer needs to distinguish a medicine acquisition decision from selecting a dispensing partner or helping patients use an access programme. Otherwise, a proposed patient saving can be incorrectly presented as clinic margin improvement.

A good answer should cover:

  • Who contracts with whom, takes title to medicine, pays each invoice and receives any credit or refund.
  • Whether the clinic controls acquisition price, service fees, routing, integration or merely patient education.
  • The exact medicine, presentation, approved or compounded status, supplying facility and intended use.
  • Separate flows for clinical-care revenue, medicine payments and operating-service charges.

Follow-up that tests the answer: “Show us which line on our own profit-and-loss statement changes if the patient’s medicine price falls.”

Evidence to request: An anonymised transaction diagram, sample invoices and an expenditure-control matrix. Do not estimate negotiable spend from patient medicine expenditure alone.

Expert quote — reserved: ________________________________________

Sources cited on this page

  1. lilly.com · Source 1 ↗https://www.lilly.com/lillydirect/faq
Section sources →